AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO025450473
Submit to EJMO
Cite this article
5
Download
63
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Clinical and oncological outcomes in colon cancer: Impact of tumor location and family history in a retrospective cohort

Ganbaatar Rentsenbalbar1 ,  Chinzorig Munkhjargal1,2 ,  Gankhuyag Gochoosuren3 ,  Namuun Ganbaatar3 ,  Tuvshinjargal Tseren4 ,  Oyungoo Badamdorj3 ,  Orgilmaa Regzedmaa3* ,  Baasanjav Nachin5*
Show Less
1 General Surgery Department, National Cancer Center of Mongolia, Ulaanbaatar, Mongolia
2 Oncology Sector, Institute of Medical Science of Mongolia, Ulaanbaatar, Mongolia
3 School of Nursing, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
4 School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
5 Department of Surgery, Ach Medical University, Ulaanbaatar, Mongolia
EJMO, 025450473 https://doi.org/10.36922/EJMO025450473
Received: 7 November 2025 | Revised: 16 February 2026 | Accepted: 7 May 2026 | Published online: 10 June 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Introduction In colorectal cancer, right-sided primary tumor location is associated with a worse prognosis compared to left-sided colon cancer.

Objective: In this study, we compared clinical, pathological, oncological characteristics, and survival between cancers of the left and right colon.

Methods: Patients who underwent curative resection for colon cancer were identified and retrospectively analyzed. Clinicopathological characteristics, overall survival, postoperative complications, and postoperative liver metastasis were compared between left- and right-sided tumors using the log-rank test and multivariable Cox proportional hazards regression.

Results: A total of 108 patients with colon adenocarcinoma were included. There was no difference in overall survival (hazard ratio [HR] = 1.08, 95% confidence interval [CI]: 0.68–1.73, p = 0.72) between right- and left-sided primary tumors. Postoperative liver recurrence was noted in 24.1% of cases, and postoperative complications occurred in 6.5% of patients, without significant differences between groups. Higher body mass index (odds ratio [OR] = 2.31, 95% CI: 1.05–15.32, p = 0.031) and larger tumor size (OR = 5.32, 95% CI: 2.82–11.14, p = 0.001) were significantly associated with colon cancer risk. Additionally, a positive family history of cancer was significantly associated with decreased overall survival (HR = 2.44, 95% CI: 1.16–5.12, p = 0.018).

Conclusion: Tumor localization was not associated with overall survival among colon cancer patients who underwent curative resection. However, a positive family history of cancer was associated with overall survival.

Keywords
Colorectal cancer
Survival time
Recovery
Funding
None.
Conflict of interest
The authors declare no conflict of interest.
References
  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834

 

  1. Yang Z, Yang Z, Bakar MZA, Deng X. Bioactivity evaluation of Polygonum minus and identification of synergistic phytochemicals with 5-fluorouracil for colon cancer treatment. Microchem J. 2025;210:112917. doi: 10.1016/j.microc.2025.112917

 

  1. Merabet A, Saighi A, Saad H, et al. AI for colon cancer: a focus on classification, detection, and predictive modeling. Int J Med Inform. 2026;206:106115. doi: 10.1016/j.ijmedinf.2025.106115

 

  1. Rajappa S, Singh M, Uehara R, Schachterle SE, Setia S. Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020. Curr Med Res Opin. 2023;39(8):1127- 1137. doi: 10.1080/03007995.2023.2231761

 

  1. Tsedendorj Y, Zorigtbaatar S, Davaasuren N-E, et al. Incidence and Mortality due to Colorectal Cancer in Mongolia, 2018- 2022. Asian Pac J Cancer Prev. 2024;25(7):2305. doi: 10.31557/APJCP.2024.25.7.2305

 

  1. Beart RW, Melton LJ, Maruta M, Dockerty MB, Frydenberg HB, O’Fallon WM. Trends in right and left-sided colon cancer. Dis Colon Rectum. 1983;26(6):393-398. doi: 10.1007/bf02553382

 

  1. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779-788. doi: 10.7326/0003-4819-113-10-779

 

  1. O’Dwyer PJ, Manola J, Valone FH, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule—an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001;19(9):2413-2421. doi: 10.1200/JCO.2001.19.9.2413

 

  1. Keivanlou M-H, Amini-Salehi E, Joukar F, et al. Family history of cancer as a potential risk factor for colorectal cancer in EMRO countries: a systematic review and meta-analysis. Sci Rep. 2023;13(1):17457. doi: 10.1038/s41598-023-44487-8

 

  1. Goosenberg E, Kaur A, Babiker HM. A review of hereditary colorectal cancers. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025.

 

  1. Armelao F, de Pretis G. Familial colorectal cancer: a review. World J Gastroenterol. 2014;20(28):9292. doi: 10.3748/wjg.v20.i28.9292

 

  1. Gervaz P, Bucher P, Morel P. Two colons‐two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88(4):261-266. doi: 10.1002/jso.20156

 

  1. Hodges N, Mackenzie H, D’Souza N, Brown G, Miskovic D. Survival outcomes for right-versus left-sided colon cancer and rectal cancer in England: a propensity-score matched population-based cohort study. Eur J Surg Oncol. 2022;48(4):841-849. doi: 10.1016/j.ejso.2021.10.007

 

  1. Szostek J, Serafin M, Mąka M, Jabłońska B, Mrowiec S. Right-Sided Versus Left-Sided Colon Cancer—A 5-Year Single-Center Observational Study. Cancers. 2025;17(3):537. doi: 10.3390/cancers17030537

 

  1. Hugen N, Van de Velde C, De Wilt J, Nagtegaal I. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014;25(3):651-657. doi: 10.1093/annonc/mdt591

 

  1. Jurescu A, Dema A, Tăban S, et al. Clinicopathological Features of Right vs. Left Colorectal Carcinomas: Do the Differences Really Matter? Life. 2026;16(2):242. doi: 10.3390/life16020242

 

  1. Joga S, Goyal S, Mehta A, et al. A Study of Molecular Subtypes (Profile) of Colorectal Cancer and Their Correlation with Clinical and Pathological Profile in a Tertiary Care Center in India. South Asian J Cancer. 2025;14(2):236-245. doi: 10.1055/s-0044-1801346

 

  1. Gutiu AG, Zhao L, Marrah AJ, et al. Promising immunotherapeutic treatments for colon cancer. Med Oncol. 2025;42(5):1-13. doi: 10.1007/s12032-025-02724-2

 

  1. Wong CC, Yu J. Gut microbiota in colorectal cancer development and therapy. Nat Rev Clin Oncol. 2023;20(7):429-452. doi: 10.1038/s41571-023-00766-x

 

  1. Dejea CM, Wick EC, Hechenbleikner EM, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. 2014;111(51):18321-18326. doi: 10.1073/pnas.1406199111

 

  1. Zhou Q, Lei L, Cheng J, et al. Microbiota-induced S100A11- RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy. Gut. 2025;74(2):214-228.doi: 10.1136/gutjnl-2024-332193

 

  1. Karim S, Brennan K, Nanji S, Berry SR, Booth CM. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3(10):1386-1392. doi: 10.1001/jamaoncol.2017.1016

 

  1. Torun M, Uzun O, Duman M, et al. Comparison of Oncological Outcomes After Curative Resection for Right-side Colon Cancer and Left-side Colon Cancer: a Retrospective Observational Study. Turk J Colorectal Dis. 2024;34(4):123-129. doi: 10.4274/tjcd.galenos.2024.2024-7-3

 

  1. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388-2394. doi: 10.1245/s10434-008-0015-y

 

  1. Suttie S, Shaikh I, Mullen R, Amin A, Daniel T, Yalamarthi S. Outcome of right‐and left‐sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13(8):884- 889. doi: 10.1111/j.1463-1318.2010.02356.x

 

  1. Jung YS, Song H, Tran MTX, Park B, Moon CM. Association between a family history of colorectal cancer and the risk of colorectal cancer: a nationwide population-based study. J Pers Med. 2022;12(10):1566. doi: 10.3390/jpm12101566

 

  1. Zenger S, Gürbüz B, Can U, et al. Differences between right and left colon cancers in terms of clinicopathological features and long-term oncological outcomes. Differences. 2020;30(4):253-260. doi: 10.4274/tjcd.galenos.2020.2020-4-6

 

  1. Diez-Alonso M, Mendoza-Moreno F, Ortega MA, et al. Differences in Colorectal Cancer Survival Based on Primary Tumor Location: Retrospective Study from a Single Institution. J Cancer. 2023;14(13):2444. doi: 10.7150/jca.85695

 

  1. Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211-219. doi: 10.1001/jamaoncol.2016.4227

 

  1. Yahagi M, Okabayashi K, Hasegawa H, Tsuruta M, Kitagawa Y. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20(3):648-655. doi: 10.1007/s11605-015-3026-6

 

  1. Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–Medicare data. J Clin Oncol. 2011;29(33):4401-4409. doi: 10.1200/JCO.2011.36.4414

 

  1. Warschkow R, Sulz MC, Marti L, et al. Better survival in right-sided versus left-sided stage I-III colon cancer patients. BMC Cancer. 2016;16(1):1-14. doi: 10.1186/s12885-016-2412-0

 

  1. Yang J, Du XL, Li ST, et al. Characteristics of differently located colorectal cancers support proximal and distal classification: a population-based study of 57,847 patients. PLoS One. 2016;11(12):e0167540. doi: 10.1371/journal.pone.0167540

 

  1. He XK, Wu W, Ding YE, Li Y, Sun LM, Si J. Different Anatomical Subsites of Colon Cancer and Mortality: A Population‐Based Study. Gastroenterol Res Pract. 2018;2018(1):7153685. doi: 10.1155/2018/7153685

 

  1. Far PM, Alshahrani A, Yaghoobi M. Quantitative risk of positive family history in developing colorectal cancer: A meta-analysis. World J Gastroenterol. 2019;25(30):4278. doi: 10.3748/wjg.v25.i30.4278

 

  1. Wong MC, Ding H, Wang J, Chan PS, Huang J. Prevalence and risk factors of colorectal cancer in Asia. Intest Res. 2019;17(3):317-329. doi: 10.5217/ir.2019.00021

 

  1. Jansson-Knodell CL, Foster NR, Sargent DJ, et al. Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance). J Gastrointest Oncol. 2017;8(1):1-11. doi: 10.21037/jgo.2016.12.13

 

  1. Ugai T, Akimoto N, Haruki K, et al. Prognostic role of detailed colorectal location and tumor molecular features: analyses of 13,101 colorectal cancer patients including 2994 early-onset cases. J Gastroenterol. 2023;58(3):229-245. doi: 10.1007/s00535-023-01955-2

 

  1. Luo Y, Cheng B, Liu S, Xu L, Wu X, Sun S. Relationship between CpG island methylation phenotype, microsatellite instability phenotype and mutation of KRAS, NRAS, and BRAF genes in colorectal cancer. Int J Clin Exp Pathol. 2019;12(3):1101.

 

  1. Liu J, Wang Y, Jiang H, Yu X, Xu N. Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy: a case report. Medicine. 2019;98(5):e14326. doi: 10.1097/MD.0000000000014326

 

  1. González-Montero J, Valenzuela G, Rojas CI, Burotto M. Sidedness matters: Colon cancer outcomes in low-resource settings. World J Clin Oncol. 2025;16(10):108937.doi: 10.5306/wjco.v16.i10.108937

 

  1. Siraj AK, Bu R, Prabhakaran S, et al. A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer. 2014;13(1):168. doi: 10.1186/1476-4598-13-168

 

  1. Caputo F, Santini C, Bardasi C, et al. BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci. 2019;20(21):5369. doi: 10.3390/ijms20215369

 

  1. Habashy P, Lea V, Wilkinson K, et al. KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort. Int J Mol Sci. 2023;24(24):17509. doi: 10.3390/ijms242417509

 

  1. Purba AP, Uwuratuw JA, Zainuddin AA, Arsyad A, Faruk M. The Relationship between Microsatellite Instability and KRAS Mutations in Liver-metastatic Colorectal Cancer: A Preliminary Cross-sectional Study. Asian Pac J Cancer Biol. 2025;10(2):315-322. doi: 10.31557/apjcb.2025.10.2.315-322

 

  1. Chen Y, Zhao N, Xu L, et al. Integrative multi-omics analysis reveals the LncRNA 60967.1–PLCD4–ATRA axis as a key regulator of colorectal cancer progression and immune response. Mol Cancer. 2025;24(1):164. doi: 10.1186/s12943-025-02359-x

 

  1. Nunes L, Li F, Wu M, et al. Prognostic genome and transcriptome signatures in colorectal cancers. Nature. 2024;633(8028):137-146. doi: 10.1038/s41586-024-07769-3

 

  1. Ji S, Hu H, Zhu R, et al. Integrative Multi-Omics Analysis Reveals Critical Molecular Networks Linking Intestinal-System Diseases to Colorectal Cancer Progression. Biomedicines. 2024;12(12):2656. doi: 10.3390/biomedicines12122656

 

  1. Qin Y, Wang Q, Lin Q, et al. Multi-omics analysis reveals associations between gut microbiota and host transcriptome in colon cancer patients. mSystems. 2025;10(3):e00805-24. doi: 10.1128/msystems.00805-24

 

  1. Alorda-Clara M, Torrens-Mas M, Morla-Barcelo PM, et al. Use of omics technologies for the detection of colorectal cancer biomarkers. Cancers. 2022;14(3):817. doi: 10.3390/cancers14030817

 

  1. Fernandez-Muñoz KV, Sánchez-Barrera CÁ, Meraz- Ríos M, et al. Natural alternatives in the treatment of colorectal Cancer: a mechanisms perspective. Biomolecules. 2025;15(3):326. doi: 10.3390/biom15030326

 

  1. Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg. 2023;15(4):495. doi: 10.4240/wjgs.v15.i4.495

 

  1. Hashem S, Ali TA, Akhtar S, et al. Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. Biomed Pharmacother. 2022;150:113054. doi: 10.1016/j.biopha.2022.113054

 

  1. Deng X, Yang Z, Chan KW, Abu Bakar MZ. Exploring the therapeutic potential of 5-fluorouracil-loaded calcium carbonate nanoparticles combined with natural compound thymoquinone for colon cancer treatment. Pharmaceutics. 2024;16(8):1011. doi: 10.3390/pharmaceutics16081011

 

  1. Deng X, Yang Z, Han M, et al. Comprehensive insights into the combinatorial uses of selected phytochemicals in colorectal cancer prevention and treatment: isothiocyanates, quinones, carotenoids, and alkaloids. Phytother Res. 2025;39(1):413-452. doi: 10.1002/ptr.8378

 

  1. Esmeeta A, Adhikary S, Dharshnaa V, et al. Plant-derived bioactive compounds in colon cancer treatment: An updated review. Biomed Pharmacother. 2022;153:113384. doi: 10.1016/j.biopha.2022.113384

 

  1. Yang Z, Chan KW, Abu Bakar MZ, Deng X. Unveiling drimenol: a phytochemical with multifaceted bioactivities. Plants. 2024;13(17):2492. doi: 10.3390/plants13172492

 

  1. Yang Z, Deng X, Yang Z, et al. Polygonum minus: A tropical medicinal herb with vast applications in food, agricultural, and medicinal fields. Food Biosci. 2024;60:104511. doi: 10.1016/j.fbio.2024.104511

 

  1. Melo RM, Albuquerque GM, Monte JP, Pereira GA, Pereira G. Recent advances in the application of silver nanoparticles for enhancing phototherapy outcomes. Pharmaceuticals. 2025;18(7):970. doi: 10.3390/ph18070970

 

  1. Yang X, Sun Y, Zhang H, et al. CaCO3 nanoplatform for cancer treatment: drug delivery and combination therapy. Nanoscale. 2024;16(14):6876-6899. doi: 10.1039/D3NR05986C

 

  1. Liang T, Feng Z, Zhang X, Li T, Yang T, Yu L. Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity. Front Bioeng Biotechnol. 2023;11:1266888. doi: 10.3389/fbioe.2023.1266888

 

  1. Deng X, Zanna MY, Ahmed H, et al. Recent progress in calcium carbonate nanoparticles for cancer therapy: design strategies and clinical prospects. Mater Res Express. 2025;12(7):072001. doi: 10.1088/2053-1591/adeb4c

 

  1. Deng X, Yang Z, Chan KW, Ismail N, Abu Bakar MZ. 5-fluorouracil in combination with calcium carbonate nanoparticles loaded with antioxidant thymoquinone against colon cancer: synergistically therapeutic potential and underlying molecular mechanism. Antioxidants. 2024;13(9):1030. doi: 10.3390/antiox13091030
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept